Company profile
VERU INC.
NASDAQ:VERUBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Sabizabulin | phase3 | — | 3 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04388826 | phase2 | completed | 2020-06-18 | 2020-12-18 | Veru Inc. | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 |
| NCT06282458 | phase2 | completed | 2024-04-29 | 2025-04-11 | Veru Inc. | Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt |
| NCT05065411 | phase3 | terminated | 2022-04-11 | 2023-10-19 | Veru Inc. | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer |
| NCT04869943 | phase3 | terminated | 2021-10-12 | 2024-01-09 | Veru Inc. | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer |
| NCT05079360 | phase2 | withdrawn | 2023-03-15 | 2024-03-30 | Veru Inc. | Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer |
FDA applications (0)
No records yet.